CoChat

Combination of Phentermine/Topiramate Er and Liraglutide 3 Mg for Intensive Therapy of Severe Obesity & T2Dm: A Case Series and Brief Review

Open access
Baloch, Harris M., Nadolsky, Karl · 2018 · AACE Clinical Case Reports

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Abstract

Objective: Patients with obesity and type 2 diabetes have severe obesity warranting intensive treatment. The medical treatment of obesity can use multiple medications that target different pathways. At present, these medications are used independently for the treatment of obesity, and there are scant data for using phentermine/topiramate (phen/top) and liraglutide combination. Methods: Here, we present interventional data and outcome of 3 obese, diabetic patients treated with these medications. Results: Patient A achieved net weight loss of 25.6% over a 30-month period on phen/top and liraglutide. This weight loss correlated with improvement in triglyceride levels (154 to 91 mg/dL), high-density lipoprotein (HDL) levels (40 to 44 mg/dL), and hemoglobin A1c (7.6 to 6.1% [60 to 43 mmol/mol]). On phen/top and liraglutide, patient B had weight loss of 11% over 24 months. Interestingly, this weight loss was correlated with an increase in triglyceride levels (116 to 231 mg/dL) and improvement in HDL (27 to 39 mg/dL). Prior to weight loss, patient was on 50 units of glargine twice daily, which was titrated off with improvement in hemoglobin A1c (15.1 to 6.2% [142 to 44 mmol/mol]). On phen/top and liraglutide, patient C had net weight loss of 27% at 18 months. This weight loss was correlated with triglyceride improvement (129 to 83 mg/dL) and HDL improvement (32 to 38 mg/dL). Prior to weight loss, patient was on 45 units of glargine, which was tapered off with an improved A1c (6.3 to 5.9% [45 to 41 mmol/mol]). Conclusion: The above cases highlight the potential for using multiple medications to target different areas for the treatment of obesity. Abbreviations: BMI = body mass index; FDA = Food and Drug Administration; HbA1c = hemoglobin A1c; HDL = high-density lipoprotein; LDL = low-density lipoprotein; phen/top = phentermine/topiramate; T2DM = type 2 diabetes mellitus

Overview

Integrity signals

Registry

Crossref · 10.4158/accr-2018-0125

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Cited by

See all 2

Metadata

Authors
Baloch, H. M., & Nadolsky, K.
Affiliations
  • Walter Reed National Military Medical Center (US)
  • Spectrum Health (US)
Corresponding author
Baloch, Harris M.
Venue
AACE Clinical Case Reports
Publisher
Elsevier BV
Published
2018-11
Volume
4
Issue
6
Pages
e482-e486
ISSN
2376-0605 (ISSN-L)
OpenAlex
W2854614634
Cited by
1
References
19
Citations by year
2022: 1
FWCI
0.00
Type
journal article
Language
en
Open access
Licence
Locations
  • AACE Clinical Case Reports (publishedVersion, cc-by-nc-nd)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
Keywords
liraglutide, morbid obesity, type 2 diabetes, combination therapy, weight loss, glycemic control, triglycerides, HDL cholesterol, GLP-1 receptor agonists, appetite suppressants

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.